Compare ATEN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | EVO |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2014 | 2021 |
| Metric | ATEN | EVO |
|---|---|---|
| Price | $17.49 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $21.50 | $7.00 |
| AVG Volume (30 Days) | ★ 734.7K | 253.2K |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 4.68 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | $284,406,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $8.10 | $8.52 |
| P/E Ratio | $25.42 | ★ N/A |
| Revenue Growth | ★ 10.27 | N/A |
| 52 Week Low | $13.81 | $2.84 |
| 52 Week High | $21.90 | $4.80 |
| Indicator | ATEN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 61.17 |
| Support Level | $17.21 | $3.10 |
| Resistance Level | $17.98 | $3.23 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 19.53 | 97.92 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.